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Abstract 
Background 
In Europe skin melanoma (SM) survival has increased over time but differences between countries 
and areas of Europe remain. 
Methods 
We calculated European relative survival estimates and geographical comparisons for 241,485 
cases of invasive SM, in ages 15 years and over, diagnosed in Europe (2000-2007), with survival 
time trends estimated using the period approach during 1999-2007, for 213,101 cases.  
Results 
In Europe, estimated 5-year relative survival was 83.2% (95% confidence interval, CI 82.9%-
83.6%). The highest values were in Northern (87.7%; 87.2%-88.2%) and Central (87.6%; 87.2%-
88.0%) Europe, followed by Ireland and UK (85.6%; 85.2%-86.0%) and Southern Europe (82.6%; 
82.1%-83.2%). The lowest survival estimate was in Eastern Europe (74.3%; 73.6%-75.1%). Within 
regions the inter-country absolute difference in percentage points of survival varied from 3.9% in 
Northern to 33.8% in Eastern Europe. Relative survival decreased markedly with age and was 
higher in women than men. Differences according to SM morphology and skin sub-sites also 
emerged. Survival has slightly increased from 1999 to 2007, with a small improvement in Northern 
and the most pronounced improvement in Eastern Europe.  
Discussion 
SM survival is high and still increasing in Europe. The gap between Northern and Southern and 
especially Eastern European countries, although still present, diminished over time. Differences in 
early detection practices may presumably explain most of the geographical differences, better 
survival in women and in younger ages. However, part of the improvement in survival may be 
attributed to overdiagnosis.  
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Introduction 
Skin melanoma (SM) incidence has increased sharply in most Western-type countries over the last 
decades; a trend that continues [1]. In 2012, SM ranked seventh among the most frequently 
diagnosed cancers in the European Union, 3.2% of all new cancers (all ages, both sexes). [2] 
The main known modifiable risk factor for SM is intermittent ultraviolet radiation exposure (UV). 
Therefore, the rise in incidence has been presumably driven by increased leisure exposure to UV 
radiation from sun and indoor tanning [3]. 
Mortality rates are still increasing in many European countries (e.g. Ireland, Sweden, Netherlands, 
etc.) [2,4] and they are nearly stable in others (e.g. Austria, Denmark, Croatia, Czech Republic, etc.) 
[2].  
According to previous EUROCARE studies, SM relative survival (RS) has increased over time [5];  
SM ranks fourth among cancers with the best survival in Europe [6].  
However, survival varies markedly between and within European regions with only a slight 
decrease in geographical differences seen over time [5]. Survival also varies across age groups and 
between sexes.  
The main prognostic factor for SM is stage at diagnosis (Breslow thickness) [7] and prompt and 
appropriate treatment. Therefore, in many countries a lot of effort is put in early diagnosis. 
However, improvements in survival do not necessarily reduce mortality [8]. In fact, overdiagnosis 
and lead time bias affect survival without preventing deaths. Therefore, differences and changes in 
survival must be interpreted with caution. 
The aim of the present EUROCARE-5 study is to provide updated data on SM RS, focusing on 
differences still present across European countries.  
 
 
Materials and methods  
We considered all adult patients (15 years and over) diagnosed in 2000-2007, with one or multiple 
invasive SM, which was defined by topography (C44.0-C44.9) and morphology (8720-8790) codes, 
according to the International Classification of Diseases for Oncology, (ICDO-3) [9].  
Overall, 241,485 cases from 29 countries (86 cancer registries [CRs]), divided into five European 
regions (Ireland and UK [Ireland/UK], Northern, Central, Southern and Eastern Europe), and 
followed up to the end of 2008 were included in the analyses. 
We estimated the age-specific (15-44, 45-54, 55-64, 65-74, and 75+ years) and age-standardised 1-
year, 5-year and 5-year relative survival conditional to surviving 1 year after diagnosis.  
We also presented the 5-year RS for different morphology and topography subgroups. In particular, 
we considered 5 morphology subgroups: superficial spreading (SSM, ICDO-3 code 8743), lentigo 
malignant (8742), nodular melanoma (8721), other specified types (8722-3, 8730, 8740-1, 8744-6, 
8761, 8770-4, 8780) and not otherwise specified (NOS, 8720) SM; and 4 topography groups: head 
and neck (C44.0-C44.4), trunk (C44.5), limbs (C44.6-C44.7), overlapping and not specified sites 
(C44.8, C44.9). 
Age-standardised incidence rates were also computed.  
We also analysed trends in 5-year RS over 1999-2001, 2002-2004, and 2005-2007, involving 
213,101 cases from the 65 CRs with  complete incidence data from at least 1996 to 2006, with the 
exception of 16 CRs from France and Spain with data from 1995 to 2004. 
 
Statistical methods 
Data collection, quality checks process and statistical methods of the EUROCARE project were 
described elsewhere in this monograph [10]. In brief, RS for cases diagnosed in 2000-2007 was 
estimated by the complete cohort approach [11] and for time trends analyses the period approach 
[10.12] was applied. The Z-test [10] was used to compare survival estimates over the study period. 
European survival estimates derived from the cohort analyses were country-weighted; whereas 
estimates in the trend analysis were area-weighted [10]. 
Both age-specific and age-standardised [13] RS were obtained by using the Ederer II method for 
expected survival [14], whereas incidence rates were age-standardised on the European standard 
population. 
The Pearson's correlation coefficient [15] was computed between age-standardised incidence rates 
and age-standardised five-year RS for the period 2000-2007, by European region. 
Finally, only the 51 out of 86 CRs with adequate morphology completeness (i.e. proportion of NOS 
SM < 30%) were included in the survival analyses for cases diagnosed in 2000-2007.  
 
Results 
The EUROCARE-5 database collected 243,417 SM diagnosed in 2000-2007 (Table 1). Cases with 
major errors, known only from death certificate (DCO), or known from autopsy alone were 
excluded from the survival analyses. The proportion of major errors was 0% or negligible for the 
majority of the registries but 5% in Cracow (Poland). Moreover, the proportions of DCO and 
autopsy cases were, respectively, low (0.4%; range 0.0%-2.7%) or negligible (0.04%; range 0.0%-
0.5%). After exclusions, 241,485 cases were included in the analyses. The proportion of 
microscopically verified cases was 98.5% (range 87.5%-100%).  
Overall Europe, 15.4% of analysed SM were located on the head and neck (range 12.9%, Southern 
Europe - 18.5%, Ireland/UK), 32.6% on the trunk (27.2%, Ireland/UK - 40.6%, Eastern Europe), 
44.3% on the limbs (36.6%, Southern Europe - 49.3%, Ireland/UK) and 7.7% on not specified (or 
overlapping) sites (4.9%, Ireland/UK - 19.1%, Southern Europe) (Table 2). 
Considering all the 86 analysed CRs, the proportion of cases with morphology NOS was 38.6% 
(Table 1), ranging from 5.7% (Biella, Italy), 6% (Doubs, France) to 93.7% (Poland, Cracow), 
96.8% (Croatia), 99.0% (Poland, Silesia) and 99.6% (Finland). Thus, not all the CRs made available 
detailed information for the requested variable. Among the 51 CRs with complete information on 
morphology (99068 cases), more than half of cases presented a SSM, whereas only 6% of cases the 
lentigo maligna. Morphology distribution was quite homogeneous among European regions, except 
for Eastern Europe showing the lowest proportion of SSM (34.7%) and the highest proportion of 
cases with morphology NOS (23.7%) (Table 2).  
The 5-year age-standardised RS for Europe was 83.2% (95% confidence interval, CI 82.9%-83.6%) 
ranging from 87.7% (95%CI 87.2%-88.2%) in Northern to 74.3% in Eastern (95% CI 73.6%-
75.1%) Europe (Figure 1). Survival estimates varied markedly among Eastern European countries 
but were relatively high and homogeneous in the other regions. The absolute difference between the 
highest and lowest survival value was 4.2 percentage points (4.2%) in Northern Europe, 7.3% in 
Central Europe, 10.7% in Ireland and UK, 17.2% in Southern Europe and 33.8% in Eastern Europe 
where almost all countries had low survival with the exception of Czech Republic (83.4%). 
One-year RS was 95.1%, with the same - but less evident - ranking across countries than 5-year RS, 
97.4% in Northern and 91.5% in Eastern Europe.  
Patients who survived one year since diagnosis had a slightly better 5-year RS than those at the time 
of diagnosis (87.5% vs. 83.2%, European average). This improvement was quite small and 
homogeneous in Northern, Central Europe and Ireland and UK (around +3 percentage points) while 
it was higher in Southern (+4.8%) and Eastern (+6.9%) Europe. 
The correlation coefficient between age-standardised survival and incidence rate was high (0.7), i.e. 
high incidence often coincided with high survival. 
Overall Europe, RS was significantly higher in women than in men: the absolute difference in RS 
between women and men was +2.2% at 1 year after diagnosis, +5.9% at 3 years and +7.4% at five 
years (Figure 1). Same results were evident for all age groups (Figure 1) and each European region. 
Differences in 5-year RS between sexes were quite stable across Europe, ranging from 5.5% in 
Central Europe to 8.6% in Ireland and UK (data not shown).  
Moreover, five-year RS decreased with advancing age, from 89.5% for patients aged 15-44 years, 
to 85.4% in the age group 45-54 years, 83.6% for 55-64 years, 80.0% for 65-74 years and 72% for 
75+ years old.  
As regards morphology, the highest survival was observed in Europe for lentigo malignant (98.4%, 
range 97.2%-99.7%), followed by SSM (94.7%; 92.8%-95.0%), SM NOS (78.2%; 60.8%-82.7%), 
other SM (76.5%; 70.5%-80.4%) and then nodular (70.0%; 63.8%-70.1%) (Figure 2a).  
Among specified morphologies, the 5-year RS for nodular and other SM in Eastern Europe was 
worse than the European average. Women had better survival for all morphologies (Figures 2b-c). 
Five-year RS estimates for skin sub-sites in Europe were: 84.9% for limbs (95% CI 73.8%-85.4%), 
80.6% for trunk (95% CI 73.8%-81.2%), 80.3% for head and neck (95% CI 73.8%-81.4%), and 
64.9% for overlapping and unspecified sites (95% CI 63.9%-66.0%). Eastern Europe showed worse 
survival for all sub-sites (Figure 3a). However, we found that survival was generally better for 
women than for men for all sub-sites (Figures 3b-c).  
Figure 4 shows trends in 5-year age-adjusted RS.  In Europe, there was a slight improvement from 
82.4% in 1999-2001 to 85.2% in the most recent period (p<0.001). The absolute difference in 
survival estimates between 2005-2007 and 1999-2001 was 0.8% (p=0.08) for Northern Europe, 
2.3% for Central (p<0.001) and Southern Europe (p=0.01), 3.1% for Ireland and UK (p<0.001) and 
5% for Eastern Europe (p<0.001). 
 
Discussion 
The present study provided survival estimates based on the widest SM dataset ever published in the 
EUROCARE project. 
Five-year RS for SM in Europe was high, 83.2%. Among the analyzed European regions, the best 
survival was found in Northern and Central Europe, then in Ireland and UK and in Southern 
Europe; Eastern Europe had the lowest survival. Areas with the best survival had the lowest inter-
country variability while Eastern Europe presented the highest variability.  
These findings confirmed previously documented geographical differences [16].  
SM survival is strongly related to the stage (Breslow thickness) at diagnosis [7]. Thinner SM have a 
better prognosis than thicker ones. Therefore, part of the geographical differences may be caused by 
different stage distribution at diagnosis. Early detection and population awareness on skin self-
examination promote the detection of thinner SM.  
Unfortunately, information of stage is not available in the present study. However, a poorer 
distribution for Breslow's thickness has been already document in Eastern countries in comparison 
with Northern and Western countries [17]. Moreover, the 1-year RS was lower in Eastern Europe 
than in other regions, which indicated a larger proportion of SM with late stage at diagnosis [18]. 
The close relationship between Breslow's thickness and prognosis legitimized those who support 
early diagnosis [19-20]. However, a favourable survival does not necessarily indicate low mortality. 
There is little evidence about the effectiveness of SM screening on mortality [21-24] and no results 
from  randomized trials evaluating mortality reduction are to be expected [22,25].  
Despite the few indications for positive screening effectiveness from observational studies, an 
improvement in survival may be at least partially apparent due to a side effect of early diagnosis 
named overdiagnosis [8,26]. This means the detection of tumours that for their nature (indolent, 
regression, etc.) or for the combination of their nature and the age of the patient would have not 
become clinically evident during the life of the patient [27]. The strong relationship between the 
increase in biopsy rate and the incidence of SM has been proposed as a clue for overdiagnosis [28] 
and, although at least part of the growth in incidence is true [29] - considering also the increase in 
mortality [2,4] - overdiagnosis is contemplated as the main explanation for the rise in trends [30].  
Therefore, differences in early diagnosis patterns could explain some of the variability in SM 
survival in Europe. The strong correlation evidenced between SM incidence and survival supports 
this hypothesis. 
Other explanations could contribute to the differences in survival, such as different socioeconomic 
status, which has been shown to be an independent prognostic factor [31]. In addition, also 
treatment differences could be involved. For example, differential use of new expensive drugs could 
become more important for SM diagnosed in more recent years, due to the availability of BRAF or 
MEK inhibitors and anti-CTLA4 monoclonal antibodies [32]. 
We also found a relationship between survival and SM morphology (worse survival for nodular SM 
and for NOS SM in Eastern Europe) and topography (worse survival for NOS and overlapping 
sites). Interpretation of SM with NOS morphology or site is difficult. As regards morphology, our 
data showed, in all the countries out of Eastern Europe, intermediate survival for NOS SM. 
Therefore, in these regions NOS seemed to represent a ‘sample’ of all the morphology types. On the 
contrary, in Eastern Europe, morphology NOS had the worst prognosis. In this case NOS seemed to 
be a proof for cases selection, e.g. patients with advanced stage at diagnosis or older ones, etc.  
In all the analysed regions survival for SM with NOS site was worse than for specified sites. 
Moreover, a geographical variation in the case-mix by morphology sub-groups could contribute to 
explain at least some of the geographical differences observed in survival. However, survival in 
Eastern Europe for nodular, other types and NOS SM, was lower than the European average 
suggesting again the role of stage at diagnosis (possibly mediated by socioeconomic status, or 
treatment differences). 
Sex has been confirmed [33] to be a strong survival predictor with better prognosis for women. The 
difference in relative survival between women and men was already present within the 1-year after 
diagnosis and increased over time. Women had better survival across all ages, skin sub-sites and 
morphologies. A better stage distribution at diagnosis has been suggested as a possible explanation 
[31] due to the supposed greater attention of women than men to their body and health. Moreover, 
an independent effect of female sex, supporting yet unknown biological factors, has also been 
suggested [34]. 
The present study confirmed that SM RS decreased with increasing age of the patients. Also the 
effect of age was presumably mediated by thickness at diagnosis [35] as a different amount of early 
diagnosis across generations. 
Five-year RS has improved over time, in all the areas and especially in Eastern countries. The 
survival levels in Northern and Central Europe were probably approaching a plateau considering the 
slowing down of the improvement during the last period of time. 
The EUROCARE standardized protocol reassured about the quality and comparability of analyzed 
data [36]. The quality of the database has been addressed in another chapter of this monograph [10]. 
However, although it is straightforward to interpret clearly an indicator of low quality, e.g. high 
proportion of patients lost to follow-up, it is more difficult to understand very high values of a 
quality index, e.g. 0% DCO or 100% microscopy verification. Also to infer the quality of histology 
reporting on the basis of the details in morphological entities definition may be fallacious; this 
could be the case of Denmark for which no detailed morphology codes have been made available 
for this study [35]. 
Due to increased incidence and higher survival, the number of people with a history of SM has risen 
in the European populations. In 2010, more than 1,000,000 European citizens were estimated to 
have had a previous SM diagnosis [37]. The increase in incidence and the improvement in survival 
will boost the number of prevalent SM patients in all the European countries. 
 
In conclusion, the heterogeneity in SM survival in Europe shows the need for the improvement in 
diagnostic activity in the Eastern countries, which all (except for Bulgaria) also have SM mortality 
rates higher than the European average [2]. The range of theoretical improvement is wide, in fact, 
there are more than 13 percentage points of differences in 5-year RS from Eastern to Northern or 
Central European Countries. Skin melanoma control and prevention should consider the possible 
overdiagnosis evaluating the improvement in survival together with those in mortality and 
incidence [38]. Moreover, primary prevention should match secondary prevention programs. 
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Figure 1. Age-specific and age-standardised relative survival for skin melanomas diagnosed in 2000-2007, by European region, country, gender and 
overall. 
Figure 2. Age-standardised 5-year relative survival (RS) for cases of both sexes (a.), and men (b.) 
and women (c.), separately, diagnosed with skin melanoma in 2000-2007, by morphological 
subgroups and European regions. 
 
aEstimates are the country-weighted European average (based on countries’ average population in 
2000-2007). 
 
Figure 3. Age-standardised 5-year relative survival (RS) for cases of both sexes (a.), and men (b.) 
and women (c.), separately, diagnosed with skin melanoma in 2000-2007, by subsite and European 
regions. 
 
aEstimates are the country-weighted European average (based on countries’ average population in 
2000-2007). 
Table 1. Quality indicators for skin melanoma cases (2000-2007) and number of cases included in the survival analayses, by registrya, European 
country and region. 
Cancer registry 
  
Cases excluded from survival 
analyses 
        Quality indicators 
Number 
of cases 
Major 
errors 
DCOa Autopsyb 
Alive with 
zero survival 
time  
Cases eligible for 
survival analyses 
Microscopically 
verified 
Unspecified 
morphology c 
 N N % N %   N % N N % N % 
Northern Europe 40,642 24 0.1 2 0.0 15.0 0.0 4 0.0 40597 40,435 99.6 21680 53.4 
Denmark 9,657 0 0.0 0 0.0 3.0 0.0 0 0.0 9654 9,548 98.9 9654 100.0 
Finland 6,217 1 0.0 1 0.0 6.0 0.1 0 0.0 6209 6,197 99.8 6183 99.6 
Iceland 404 0 0.0 0 0.0 0.0 0.0 0 0.0 404 403 99.8 153 37.8 
Norway 8,600 23 0.3 1 0.0 1.0 0.0 0 0.0 8575 8,532 99.5 1786 20.8 
Sweden 15,764 0 0.0 0 0.0 5.0 0.0 4 0.0 15755 15,755 100.0 3904 24.8 
Ireland and UK 76,163 12 0.0 388 0.5 1.0 0.0 1 0.0 75761 73,841 97.5 27859 36.8 
Ireland 4,459 1 0.0 6 0.1 1.0 0.0 0 0.0 4451 4,429 99.5 1807 40.6 
UK, England 59,510 9 0.0 346 0.6 0.0 0.0 0 0.0 59155 57,735 97.6 22718 38.4 
UK, Northern Ireland  1,824 1 0.1 1 0.1 0.0 0.0 0 0.0 1822 1,809 99.3 287 15.7 
UK, Scotland  6,778 0 0.0 3 0.0 0.0 0.0 1 0.0 6774 6,754 99.7 1433 21.2 
UK, Wales  3,592 1 0.0 32 0.9 0.0 0.0 0 0.0 3559 3,114 87.5 1614 45.4 
Central Europe 69,812 2 0.0 374 0.5 4.0 0.0 667 1.0 68765 68,085 99.0 19261 28.0 
Austria  8,545 2 0.0 0 0.0 0.0 0.0 0 0.0 8543 8,423 98.6 5269 61.7 
Belgium 6,387 0 0.0 0 0.0 0.0 0.0 185 2.9 6202 6,159 99.3 2559 41.3 
France 4,648 0 0.0 0 0.0 0.0 0.0 356 7.7 4292 4,284 99.8 615 14.3 
Bas Rhin 754 0 0.0 0 0.0 0.0 0.0 9 1.2 745 743 99.7 169 22.7 
Calvados 321 0 0.0 0 0.0 0.0 0.0 11 3.4 310 309 99.7 50 16.2 
Doubs 282 0 0.0 0 0.0 0.0 0.0 5 1.8 277 277 100.0 17 6.0 
Herault 513 0 0.0 0 0.0 0.0 0.0 23 4.5 490 490 100.0 66 13.5 
Isere 667 0 0.0 0 0.0 0.0 0.0 78 11.7 589 589 100.0 42 7.0 
Loire Atlantique e 1,352 0 0.0 0 0.0 0.0 0.0 190 14.1 1162 1,160 99.8 187 16.1 
Manche 283 0 0.0 0 0.0 0.0 0.0 29 10.2 254 254 100.0 33 13.1 
Somme 262 0 0.0 0 0.0 0.0 0.0 10 3.8 252 249 98.9 33 13.0 
Tarn 214 0 0.0 0 0.0 0.0 0.0 1 0.5 213 213 100.0 18 8.4 
Germany 21,491 0 0.0 370 1.7 1.0 0.0 77 0.4 21043 20543 97.6 5859 27.8 
Brandeburg 2,574 0 0.0 56 2.2 0.0 0.0 0 0.0 2518 2,445 97.1 839 33.3 
Bremen 820 0 0.0 20 2.4 0.0 0.0 1 0.1 799 777 97.2 244 30.5 
Hamburg 2,509 0 0.0 34 1.4 0.0 0.0 1 0.0 2474 2,410 97.4 1602 64.8 
Mecklenburg-
Vorpommern 1,704 0 0.0 46 2.7 0.0 0.0 0 0.0 1658 1,610 97.1 406 24.5 
Munich 4,532 0 0.0 12 0.3 0.0 0.0 75 1.7 4445 4,445 100.0 607 13.7 
Northrhine Westfalia 2,973 0 0.0 58 2.0 1.0 0.0 0 0.0 2914 2,771 95.1 816 28.0 
Saarland 1,264 0 0.0 16 1.3 0.0 0.0 0 0.0 1248 1,228 98.4 364 29.2 
Saxony 5,115 0 0.0 128 2.5 0.0 0.0 0 0.0 4987 4,857 97.4 981 19.7 
Switzerland 4,185 0 0.0 4 0.1 3.0 0.1 47 1.1 4131 4,122 99.8 779 18.9 
Basel 812 0 0.0 3 0.4 1.0 0.1 47 5.8 761 756 99.3 73 9.6 
Geneva 995 0 0.0 1 0.1 2.0 0.2 0 0.0 992 989 99.7 215 21.7 
Grisons 374 0 0.0 0 0.0 0.0 0.0 0 0.0 374 374 100.0 65 17.4 
St. Gallen 820 0 0.0 0 0.0 0.0 0.0 0 0.0 820 820 100.0 180 22.0 
Ticino 667 0 0.0 0 0.0 0.0 0.0 0 0.0 667 666 99.9 179 26.8 
Valais 517 0 0.0 0 0.0 0.0 0.0 0 0.0 517 517 100.0 67 12.9 
The Netherlands  24,556 0 0.0 0 0.0 0.0 0.0 2 0.0 24554 24,554 100.0 4180 17.0 
Southern Europe 31,008 58 0.2 45 0.1 1.0 0.0 98 0.3 30806 30,440 98.8 13337 43.3 
Croatia  3,812 0 0.0 0 0.0 0.0 0.0 0 0.0 3812 3,808 99.9 3689 96.8 
Italy 17,849 1 0.0 27 0.2 0.0 0.0 8 0.0 17813 17,521 98.4 5415 30.4 
Alto Adige 578 0 0.0 0 0.0 0.0 0.0 0 0.0 578 576 99.7 38 6.6 
Biella 212 0 0.0 1 0.5 0.0 0.0 0 0.0 211 210 99.5 12 5.7 
Catanzaro 49 0 0.0 0 0.0 0.0 0.0 0 0.0 49 49 100.0 6 12.2 
Ferrara 384 0 0.0 0 0.0 0.0 0.0 0 0.0 384 383 99.7 80 20.8 
Firenze-Prato 1,240 0 0.0 1 0.1 0.0 0.0 1 0.1 1238 1,181 95.4 198 16.0 
Friuli Venezia Giulia 1,882 0 0.0 0 0.0 0.0 0.0 0 0.0 1882 1,882 100.0 770 40.9 
Genova 788 0 0.0 5 0.6 0.0 0.0 0 0.0 783 762 97.3 126 16.1 
Latina 510 0 0.0 6 1.2 0.0 0.0 1 0.2 503 443 88.0 158 31.4 
Mantova 223 0 0.0 0 0.0 0.0 0.0 0 0.0 223 222 99.6 136 61.0 
Milano 1,694 0 0.0 0 0.0 0.0 0.0 3 0.2 1691 1,689 99.9 358 21.2 
Modena 697 0 0.0 0 0.0 0.0 0.0 0 0.0 697 697 100.0 130 18.7 
Napoli 233 0 0.0 0 0.0 0.0 0.0 1 0.4 232 231 99.6 65 27.9 
Nuoro 25 0 0.0 0 0.0 0.0 0.0 0 0.0 25 25 100.0 10 40.0 
Palermo 350 0 0.0 3 0.9 0.0 0.0 0 0.0 347 308 88.9 95 27.4 
Parma 542 0 0.0 0 0.0 0.0 0.0 0 0.0 542 542 100.0 53 9.8 
Ragusa 173 0 0.0 1 0.6 0.0 0.0 0 0.0 172 167 97.1 34 19.7 
Reggio Emilia 478 0 0.0 0 0.0 0.0 0.0 0 0.0 478 473 99.0 290 60.7 
Romagna 1,556 0 0.0 2 0.1 0.0 0.0 0 0.0 1554 1,535 98.8 233 15.0 
Salerno 497 0 0.0 3 0.6 0.0 0.0 2 0.4 492 474 96.4 186 37.8 
Sassari 180 0 0.0 1 0.6 0.0 0.0 0 0.0 179 175 97.8 54 30.0 
Siracusa 206 0 0.0 1 0.5 0.0 0.0 0 0.0 205 200 97.6 29 14.1 
Sondrio 179 0 0.0 0 0.0 0.0 0.0 0 0.0 179 178 99.4 28 15.6 
Torino 1,179 1 0.1 0 0.0 0.0 0.0 0 0.0 1178 1,174 99.7 305 25.9 
Trapani 124 0 0.0 0 0.0 0.0 0.0 0 0.0 124 123 99.2 11 8.9 
Trentino 402 0 0.0 0 0.0 0.0 0.0 0 0.0 402 402 100.0 103 25.6 
Umbria 815 0 0.0 0 0.0 0.0 0.0 0 0.0 815 811 99.5 234 28.7 
Varese 577 0 0.0 0 0.0 0.0 0.0 0 0.0 577 571 99.0 123 21.3 
Veneto 2,076 0 0.0 3 0.1 0.0 0.0 0 0.0 2073 2,038 98.3 1550 74.8 
Malta 280 1 0.4 3 1.1 0.0 0.0 1 0.4 275 266 96.8 108 39.3 
Portugal 3257 55 1.7 1 0.0 0.0 0.0 33 1.0 3168 3134 98.9 2305 72.8 
Açores 84 0 0.0 1 1.2 0.0 0.0 2 2.4 81 80 98.8 60 73.8 
Northern Portugal 1,065 0 0.0 0 0.0 0.0 0.0 18 1.7 1047 1,047 100.0 733 70.0 
Southern  Portugal 2,108 55 2.6 0 0.0 0.0 0.0 13 0.6 2040 2,007 98.4 1512 74.1 
Slovenia National 2,629 0 0.0 0 0.0 1.0 0.0 0 0.0 2628 2,628 100.0 890 33.9 
Spain 3,181 1 0.0 14 0.4 0.0 0.0 56 1.8 3110 3083 99.1 930 29.9 
Basque Country 1,067 0 0.0 6 0.6 0.0 0.0 11 1.0 1050 1,044 99.4 378 36.0 
Cuenca 62 0 0.0 0 0.0 0.0 0.0 0 0.0 62 62 100.0 15 24.2 
Girona 409 1 0.2 2 0.5 0.0 0.0 8 2.0 398 393 98.8 60 15.0 
Granada 408 0 0.0 0 0.0 0.0 0.0 0 0.0 408 404 99.0 71 17.4 
Murcia 450 0 0.0 2 0.4 0.0 0.0 37 8.2 411 406 98.7 81 19.8 
Navarra 397 0 0.0 1 0.3 0.0 0.0 0 0.0 396 394 99.5 132 33.2 
Tarragona 388 0 0.0 3 0.8 0.0 0.0 0 0.0 385 380 98.7 193 50.0 
Eastern Europe 25,792 31 0.1 97 0.4 80.0 0.3 28 0.1 25556 25,174 98.5 11540 45.2 
Bulgaria 2,722 0 0.0 2 0.1 0.0 0.0 0 0.0 2720 2,717 99.9 2106 77.4 
Czech Republic 13,087 0 0.0 0 0.0 70.0 0.5 14 0.1 13003 13,003 100.0 4238 32.6 
Estonia 1,027 0 0.0 2 0.2 2.0 0.2 0 0.0 1023 1,014 99.1 214 21.0 
Latvia 1,265 4 0.3 21 1.7 5.0 0.4 0 0.0 1235 1,182 95.7 671 54.3 
Lithuania  1,554 0 0.0 1 0.1 0.0 0.0 2 0.1 1551 1,549 99.9 1208 77.9 
Poland 2,496 27 1.1 2 0.1 1.0 0.0 14 0.6 2452 2,282 93.1 2145 87.5 
Cracow 522 27 5.2 0 0.0 1.0 0.2 5 1.0 489 489 100.0 458 93.7 
Kielce 623 0 0.0 1 0.2 0.0 0.0 0 0.0 622 622 100.0 440 70.8 
Silesia 1,267 0 0.0 0 0.0 0.0 0.0 7 0.6 1260 1,171 92.9 1247 99.0 
Slovakia 3,725 0 0.0 70 1.9 2.0 0.1 0 0.0 3653 3,427 93.8 958 26.2 
Europe 243,417 127 0.1 906 0.4 101.0 0.0 798 0.3 241485 237,975 98.5 93213 38.6 
 
 
 
 
a Data from European 86 cancer registries 
b Cases known by death certificate 
c Diagnosed incidentally at autopsy 
d Proportion of patients diagnosed while alive in 2000–03, censored with less than 5 years of follow-up. For the French registries this quality indicator 
was calculated for cases diagnosed in 2000–02  
e Morphology not otherwise specified 
f Specialised cancer registry till 1997 
 
Table 2. Distribution of topographya and morphologyb subgroups for skin melanoma cases diagnosed in 2000-2007, overall and by European 
region. 
     European regions 
Codes 
  
Northern 
Europe 
Ireland 
and UK 
Central 
Europe 
Southern 
Europe 
Eastern 
Europe 
Europe 
Morphology  
Nodular melanoma 8721 N 4,546 1,043 6,924 1,431 818 14,762 
 % 18.70 12.10 14.40 10.80 17.50 14.90 
Lentigo maligna 8742 N 1,217 968 2,995 520 235 5,935 
 % 5.00 11.30 6.20 3.90 5.00 6.00 
Superficial 
spreading 
8743 N 12,610 4,341 27,324 5,953 1,623 51,851 
 % 51.80 50.50 56.70 45.00 34.70 52.30 
Other specified 
types 
c 
N 498 556 2,656 2,981 894 7,585 
 % 2.00 6.50 5.50 22.50 19.10 7.70 
NOS 8720 N 5,459 1,688 8,330 2,352 1,106 18,935 
 % 22.40 19.60 17.30 17.80 23.70 19.10 
All cases  N 24,330 8,596 48,229 13,237 4,676 99,068 
Topography  
Head and neck C44.0-C44.4 N 5,543 13,983 10,106 3,971 3,642 37,245 
 % 13.7 18.5 14.7 12.9 14.3 15.4 
Trunk C44.5 N 15,888 20,753 21,969 9,682 10,383 78,675 
 % 39.1 27.4 31.9 31.4 40.6 32.6 
Limbs C44.6-C44.7 N 16,733 37,332 31,632 11,269 9,973 106,939 
 % 41.2 49.3 46 36.6 39 44.3 
Not specified sites C44.8-C44.9 N 2,433 3,693 5,058 5,884 1,558 18,626 
  % 6 4.9 7.4 19.1 6.1 7.7 
All cases  N 40597 75,761 68,765 30,806 25,556 241,485 
a Data from 86 European cancer registries (CRs); b Data from 51/86 CRs with adequate information on morphology (arbitrarily defined as <30% not 
otherwise specified [NOS] morphology codes 8720); c Comprising the following morphology codes: 8722-3, 8730, 8740-1, 8744-6, 8761, 8770-4, 8780 
 
 
